A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer

✍ Scribed by Mary Morrogh; Thomas J. Miner; Anna Park; Ann Jenckes; Mithat Gonen; Andrew Seidman; Monica Morrow; David P. Jaques; Tari A. King

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 243 KB
• Volume: 116
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.25034

✦ Synopsis

Abstract

BACKGROUND:

Although systemic therapy for metastatic breast cancer (MBC) continues to evolve, there are scant data to guide physicians and patients when symptoms develop. In this article, the authors report the frequency and durability of palliative procedures performed in the setting of MBC.

METHODS:

From July 2002 to June 2003, 91 patients with MBC underwent 109 palliative procedures (operative, n = 76; IR n = 39, endoscopic n = 3). At study entry, patients had received a mean of 6 prior systemic therapies for metastatic disease. System‐specific symptoms included neurologic (33%), thoracic (23%), musculoskeletal (22%) and GI (14%). The most common procedures were thoracostomy with or without pleurodesis (27%), craniotomy with resection (19%) and orthopedic open reduction/internal fixation (19%).

RESULTS:

Symptom improvement at 30 days and 100 days was reported by 91% and 81% of patients, respectively, and 70% reported continued benefit for duration of life. At a median interval of 75 days from intervention (range, 8‐918 days), 23 patients (25%) underwent 61 additional procedures for recurrent symptoms. The durability of palliation varied with system‐specific symptoms. Patients with neurologic or musculoskeletal symptoms were least likely to require additional maintenance procedures (P < .0002). The 30‐day complication rate was 18% and there were no procedure‐related deaths. At a median survival of 37.4 mos from MBC diagnosis (range, 1.6‐164 months) and 8.4 months after intervention (range, 0.2‐73 months), 7 of 91 patients remained alive.

CONCLUSIONS:

Palliative interventions for symptoms of MBC are safe and provide symptom control for the duration of life in 70% of patients. Definitive surgical treatment of neurologic or musculoskeletal symptoms provided the most durable palliation; interventions for other symptoms frequently require subsequent procedures. The longer median survival for patients with MBC highlights the need to optimize symptom control to maintain quality of life. Cancer 2010. © 2010 American Cancer Society.